Bridgeway Capital Management’s MAIA Biotechnology MAIA Stock Holding History

Bridgeway Capital Management’s Portfolio MAIA Stock Details MAIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$109K	Buy	76,000 +40,000	+111%	+$53.1K	﹤0.01%	1140
2026 Q1	$50.4K	Hold	36,000	–	–	﹤0.01%	1187
2025 Q4	$55.1K	Hold	36,000	–	–	﹤0.01%	1179
2025 Q3	$55.4K	Hold	36,000	–	–	﹤0.01%	1161
2025 Q2	$64.8K	Hold	36,000	–	–	﹤0.01%	1117
2025 Q1	$55.1K	Sell	36,000 -9,700	-21%	-$18K	﹤0.01%	1115
2024 Q4	$90.5K	Hold	45,700	–	–	﹤0.01%	1119
2024 Q3	$128K	Hold	45,700	–	–	﹤0.01%	1128
2024 Q2	$156K	Hold	45,700	–	–	﹤0.01%	1102
2024 Q1	$101K	Sell	45,700 -30,000	-40%	-$45K	﹤0.01%	1208
2023 Q4	$88.6K	Buy	75,700 +24,100	+47%	+$38.9K	﹤0.01%	1258
2023 Q3	$114K	Buy	51,600 +25,000	+94%	+$49.5K	﹤0.01%	1203
2023 Q2	$58.5K	Buy	+26,600	New	+$71.2K	﹤0.01%	1326

Other funds holding MAIA

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

CWM

Centric Wealth Management Chicago, Illinois $643M AUM 21% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bridgeway Capital Management's MAIA Position: Q2 2026 in Review

Bridgeway Capital Management increased its MAIA Biotechnology (MAIA) stake by 111% in Q2 2026, buying an estimated $53.1K and bringing the position to 76,000 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #1140.

Bridgeway Capital Management first reported a position in MAIA in Q2 2023 and has held it in 13 quarters since. The position peaked at $156K in Q2 2024. 36 funds tracked by Wall St. Rank hold MAIA as of Q2 2026.

Bridgeway Capital Management held 76,000 shares of MAIA Biotechnology worth $109K as of Q2 2026.
Bridgeway Capital Management bought 40,000 MAIA Biotechnology shares in Q2 2026, an estimated $53.1K.
MAIA Biotechnology made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #1140 holding.
Bridgeway Capital Management first reported a position in MAIA Biotechnology in Q2 2023 and has held it in 13 quarters since.
Bridgeway Capital Management's MAIA Biotechnology position peaked at $156K in Q2 2024.
36 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.